NEW YORK (GenomeWeb News) – BioView and ScreenCell today announced a deal to develop a circulating tumor cell analysis technology.
The agreement seeks to combine ScreenCell's technology for isolating rare cells that may have prognostic and predictive value in cancer and BioView's scanning platform, which provides automated imaging and analysis solutions for rare cell and circulating tumor cell detection.
ScreenCell CEO David Znaty said in a statement, "Our objective is to support a breakthrough in personalized medicine by creating a non-invasive evaluation of specific therapeutic targets and 'real time' monitoring of target evolution which we strongly believe will be facilitated by combining ScreenCell and BioView technologies."
BioView is based in Rehovot, Israel and its Imaging Systems use field-proven algorithms and accommodate "both the need for CTC enumeration and retrieval of cellular and marker characteristics of captured cells," the company said.
Paris-based ScreenView's technologies isolate tumor cells by size and characterize them. The devices can be used for mesenchymal cells, cancer stem cells, microemboli, and cancer cells of non-epithelial origin.
Terms of the deal were not disclosed.